By Fineline Cube 
Amgen Inc. (NASDAQ: AMGN) announced that China’s National Medical Products Administration (NMPA) has accepted for review a New Drug Application (NDA) for Izervay (avacincaptad pegol, ACP), seeking approval for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Application Type | New Drug Application (NDA) accepted for review |
| Product | Izervay (avacincaptad pegol, ACP) |
| Indication | Geographic atrophy secondary to age-related macular degeneration |
| Acquisition Details | Licensed from Iveric Bio in July 2023 for USD 5.9 billion |
| US Approval | August 2023 |
| Review Basis | GATHER1 and GATHER2 pivotal studies + high unmet medical need |
This NDA acceptance represents Amgen’s strategic entry into China’s ophthalmology market, targeting a condition with no currently approved treatments in the country.
Drug Profile & Mechanism of Action
- Molecule: Avacincaptad pegol (ACP), a synthetic aptamer
- Target: Complement C5 protein
- Mechanism: Inhibits overactivation of the complement system, reducing retinal cell degeneration and slowing GA progression
- Administration: Monthly intravitreal injection (2 mg dose)
- Therapeutic Rationale: Complement system overactivation drives scarring and vision loss in GA secondary to AMD
Izervay’s targeted approach addresses the root cause of GA progression rather than merely managing symptoms, representing a paradigm shift in AMD treatment.
Clinical Evidence Summary
| Study | Phase | Primary Endpoint | GA Lesion Growth Reduction (12 months) |
|---|---|---|---|
| GATHER1 | II/III | Statistically significant | 35% reduction vs. sham |
| GATHER2 | III | Statistically significant | 18% reduction vs. sham |
| Combined Analysis | Pivotal | Met with robust statistical significance | Consistent benefit across studies |
Both pivotal trials demonstrated that monthly 2 mg intravitreal injections significantly slowed the rate of GA lesion expansion compared to sham treatment, establishing a clinically meaningful benefit for patients with progressive vision loss.
Competitive Landscape & Market Opportunity
| Therapeutic Status | China | Global Context |
|---|---|---|
| Approved GA treatments | None currently approved | Syfovre (pegcetacoplan) and Izervay approved in US |
| Pipeline candidates | Limited visibility | Multiple complement inhibitors in development |
| Patient population | Estimated 3-5 million GA patients | Represents largest untapped ophthalmology market globally |
| Treatment gap | Complete absence of disease-modifying therapies | High unmet medical need acknowledged by NMPA |
China’s GA market represents one of the largest untapped opportunities in ophthalmology, with an aging population driving increasing prevalence of AMD and its complications.
Strategic Implications for Amgen
- Geographic Expansion: Successful approval would establish Amgen’s first ophthalmology franchise in China
- Premium Pricing Potential: First-mover advantage in a high-unmet-need indication supports premium reimbursement
- Franchise Building: Validates Amgen’s $5.9 billion acquisition of Iveric Bio and opens door for additional ophthalmology pipeline assets
- Healthcare System Impact: Addresses critical gap in China’s eye care services, potentially qualifying for expedited reimbursement pathways
The NMPA’s acceptance of the NDA, coupled with explicit recognition of high unmet medical need, suggests favorable regulatory conditions for potential approval in 2027.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial potential for Izervay. Actual results may differ due to risks including final regulatory decisions, competitive dynamics, and market access challenges.-Fineline Info & Tech